Home
VSTM
VSTM News

Latest Verastem Inc. (VSTM) News on December 22, 2024

Applied Therapeutics Appoints John H. Johnson as Executive Chairman

GlobeNewswire

2 days ago

Applied Therapeutics Appoints John H. Johnson as Executive Chairman

MT Newswires

4 days ago

Mizuho Raises Price Target on Verastem to $9 From $7, Keeps Outperform Rating

Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Business Wire

4 days ago

Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference

Business Wire

a month ago

Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference

Associated Press Finance

2 months ago

Verastem: Q3 Earnings Snapshot

Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Business Wire

2 months ago

Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Verastem Oncology submits NDA for ovarian cancer treatment

Pharmaceutical Technology

2 months ago

Verastem Oncology submits NDA for ovarian cancer treatment

MT Newswires

2 months ago

Verastem Completes Rolling NDA Submission to US FDA for Drug Combination to Treat Rare Ovarian Cancer

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Business Wire

2 months ago

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Verastem Oncology to Participate in Upcoming Investor Conferences

Business Wire

2 months ago

Verastem Oncology to Participate in Upcoming Investor Conferences

MT Newswires

2 months ago

Verastem Reports Updated Data on Phase 2 Study of Ovarian Cancer Combination Therapy

Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting

Business Wire

2 months ago

Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting

Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting

Business Wire

2 months ago

Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

3 months ago

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

3 months ago

Guggenheim Initiates Coverage on Verastem With Buy Rating, $13 Price Target

Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference

Business Wire

3 months ago

Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference

Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting

Business Wire

3 months ago

Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting

Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024

Business Wire

4 months ago

Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024

MT Newswires

4 months ago

RBC Adjusts Price Target on Verastem to $13 From $16, Maintains Outperform Rating

Associated Press Finance

4 months ago

Verastem: Q2 Earnings Snapshot

Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates

Business Wire

4 months ago

Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates

MT Newswires

5 months ago

Verastem Gets FDA Orphan Drug Designation for Avutometinib With Defactinib to Treat Pancreatic Cancer

Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer

Business Wire

5 months ago

Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer

MT Newswires

5 months ago

B. Riley Adjusts Verastem's PT to $7 From $21, Maintains Buy Rating

MT Newswires

5 months ago

Top Premarket Decliners

Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants

Business Wire

5 months ago

Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants

Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants

Business Wire

5 months ago

Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants

Verastem (VSTM) Begins Dosing in Solid Tumors Study in China

Zacks

5 months ago

Verastem (VSTM) Begins Dosing in Solid Tumors Study in China

Verastem announces dosing of first patient in trial of KRAS G12D inhibitor

Clinical Trials Arena

5 months ago

Verastem announces dosing of first patient in trial of KRAS G12D inhibitor

MT Newswires

5 months ago

Sector Update: Health Care Stocks Higher in Late Afternoon Trading

MT Newswires

5 months ago

Verastem Says First Patient Dosed in Phase 1/2 Solid Tumor Trial in China

Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet Therapeutics

Business Wire

5 months ago

Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet Therapeutics

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

5 months ago

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

5 months ago

Truist Securities Adjusts Price Target on Verastem to $18 From $34, Notes Recent Stock Pull Back; Maintains Buy Rating

Verastem Oncology Announces Addition to Russell 3000® and Russell Microcap® Indexes

Business Wire

6 months ago

Verastem Oncology Announces Addition to Russell 3000® and Russell Microcap® Indexes

MT Newswires

7 months ago

RBC Halves Price Target on Verastem to $16 From $32, Maintains Outperform Rating, Speculative Risk Qualifier

MT Newswires

7 months ago

Top Midday Decliners

Verastem (VSTM) Up on Upbeat Early Pancreatic Cancer Study Data

Zacks

7 months ago

Verastem (VSTM) Up on Upbeat Early Pancreatic Cancer Study Data

What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday?

Benzinga

7 months ago

What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday?

MT Newswires

7 months ago

Sector Update: Health Care Stocks Advance Pre-Bell Friday

ASCO 2024: Verastem’s combo therapy for pancreatic cancer hits early trial success

Pharmaceutical Technology

7 months ago

ASCO 2024: Verastem’s combo therapy for pancreatic cancer hits early trial success

ASCO 2024: Verastem’s combo therapy for pancreatic cancer hits early trial success

Clinical Trials Arena

7 months ago

ASCO 2024: Verastem’s combo therapy for pancreatic cancer hits early trial success

MT Newswires

7 months ago

Verastem Reports Results of Potential Pancreatic Cancer Treatment, Submits Rolling New Drug Application for Rare Ovarian Cancer

Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Business Wire

7 months ago

Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer

Business Wire

7 months ago

Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer

Associated Press Finance

7 months ago

Verastem: Q1 Earnings Snapshot

Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates

Business Wire

7 months ago

Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates

Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference

Business Wire

8 months ago

Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference

Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer

Business Wire

8 months ago

Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

9 months ago

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer

Business Wire

9 months ago

Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer

Associated Press Finance

9 months ago

Verastem: Q4 Earnings Snapshot

Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates

Business Wire

9 months ago

Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates

Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs

Business Wire

9 months ago

Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs

Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Business Wire

10 months ago

Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024

Business Wire

10 months ago

Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024

Andreas Halvorsen's Viking Global Investors LP Bolsters Position in Verastem Inc

GuruFocus.com

10 months ago

Andreas Halvorsen's Viking Global Investors LP Bolsters Position in Verastem Inc

Director Robert Gagnon Sells 9,204 Shares of Verastem Inc (VSTM)

GuruFocus.com

10 months ago

Director Robert Gagnon Sells 9,204 Shares of Verastem Inc (VSTM)

3 Stocks That AI Predicts Will Deliver Triple-Digit Returns This Year: February 2024

InvestorPlace

10 months ago

3 Stocks That AI Predicts Will Deliver Triple-Digit Returns This Year: February 2024

GCM Grosvenor to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Investor Conference Call on February 13, 2024

GlobeNewswire

a year ago

GCM Grosvenor to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Investor Conference Call on February 13, 2024

Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers

Business Wire

a year ago

Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers

LSI Industries (NASDAQ:LYTS) Has Affirmed Its Dividend Of $0.05

Simply Wall St.

a year ago

LSI Industries (NASDAQ:LYTS) Has Affirmed Its Dividend Of $0.05

Blackstone and Other Asset Manager Stocks Have Soared. Earnings Shouldn’t Disappoint.

Barrons.com

a year ago

Blackstone and Other Asset Manager Stocks Have Soared. Earnings Shouldn’t Disappoint.

MarineMax Inc (HZO) Reports Record Q1 Revenue Amidst Retail Challenges

GuruFocus.com

a year ago

MarineMax Inc (HZO) Reports Record Q1 Revenue Amidst Retail Challenges

Heron (HRTX) Gains 19% on FDA Nod for Zynrelef Label Expansion

Zacks

a year ago

Heron (HRTX) Gains 19% on FDA Nod for Zynrelef Label Expansion

Cathay General (CATY) Beats Q4 Earnings and Revenue Estimates

Zacks

a year ago

Cathay General (CATY) Beats Q4 Earnings and Revenue Estimates

Magic Software Enterprises Ltd.'s (NASDAQ:MGIC) Stock Has Fared Decently: Is the Market Following Strong Financials?

Simply Wall St.

a year ago

Magic Software Enterprises Ltd.'s (NASDAQ:MGIC) Stock Has Fared Decently: Is the Market Following Strong Financials?

CONSOL Energy (CEIX) Returned 61% Despite 25% Fall in Estimates

Insider Monkey

a year ago

CONSOL Energy (CEIX) Returned 61% Despite 25% Fall in Estimates

American Coastal Insurance Reaches US$505m Market Cap Benefiting Insider Stock Buying

Simply Wall St.

a year ago

American Coastal Insurance Reaches US$505m Market Cap Benefiting Insider Stock Buying

Verastem (VSTM) Up 8% on Fast Track Tag for NSCLC Combo Therapy

Zacks

a year ago

Verastem (VSTM) Up 8% on Fast Track Tag for NSCLC Combo Therapy

Consolidated Communications Reminds Shareholders to Vote FOR the Value Maximizing Transaction Today

Business Wire

a year ago

Consolidated Communications Reminds Shareholders to Vote FOR the Value Maximizing Transaction Today

Baijiayun Announces Changes in Management and Board of Directors

PR Newswire

a year ago

Baijiayun Announces Changes in Management and Board of Directors

Reuters

a year ago

CORRECTED-SEC probes B. Riley deals with client tied to failed hedge fund - Bloomberg News

When Will Invivyd, Inc. (NASDAQ:IVVD) Become Profitable?

Simply Wall St.

a year ago

When Will Invivyd, Inc. (NASDAQ:IVVD) Become Profitable?

Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)

Business Wire

a year ago

Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)

Why Calavo Growers (CVGW) Stock Is Trading Lower Today

StockStory

a year ago

Why Calavo Growers (CVGW) Stock Is Trading Lower Today

NEUBERGER BERMAN MUNICIPAL FUND ANNOUNCES MONTHLY DISTRIBUTION

PR Newswire

a year ago

NEUBERGER BERMAN MUNICIPAL FUND ANNOUNCES MONTHLY DISTRIBUTION

Chatham Lodging Trust Announces Fourth Quarter Earnings Call to be Held on Tuesday, February 27, 2024

Business Wire

a year ago

Chatham Lodging Trust Announces Fourth Quarter Earnings Call to be Held on Tuesday, February 27, 2024

Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference

Business Wire

a year ago

Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference

abrdn U.S. Closed-End Funds Announce Distribution Payment Details

ACCESSWIRE

a year ago

abrdn U.S. Closed-End Funds Announce Distribution Payment Details

Taseko Announces a 26% Increase in Annual Copper Production from its Gibraltar Mine

PR Newswire

a year ago

Taseko Announces a 26% Increase in Annual Copper Production from its Gibraltar Mine

Roadzen Appoints Jean-Noël Gallardo as Global Chief Financial Officer

GlobeNewswire

a year ago

Roadzen Appoints Jean-Noël Gallardo as Global Chief Financial Officer

Business Wire

a year ago

Xponential Fitness, Inc. Provides 2023 Operating Highlights

Owning 48% shares,institutional owners seem interested in Aura Biosciences, Inc. (NASDAQ:AURA),

Simply Wall St.

a year ago

Owning 48% shares,institutional owners seem interested in Aura Biosciences, Inc. (NASDAQ:AURA),

Praxis Precision Medicines Announces Licensing and Collaboration Agreement with Tenacia Biotechnology for Ulixacaltamide in Greater China

GlobeNewswire

a year ago

Praxis Precision Medicines Announces Licensing and Collaboration Agreement with Tenacia Biotechnology for Ulixacaltamide in Greater China

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

a year ago

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Resources Connection Inc (RGP) Faces Revenue Decline Amid Economic Challenges in Q2 Fiscal 2024

GuruFocus.com

a year ago

Resources Connection Inc (RGP) Faces Revenue Decline Amid Economic Challenges in Q2 Fiscal 2024

Nerdy to Participate in Needham Growth Conference

Business Wire

a year ago

Nerdy to Participate in Needham Growth Conference

Zacks.com featured highlights include REX American Resources, Consolidated Water and Beacon Roofing Supply

Zacks

a year ago

Zacks.com featured highlights include REX American Resources, Consolidated Water and Beacon Roofing Supply

Sprinklr (NYSE:CXM) Shareholders Will Want The ROCE Trajectory To Continue

Simply Wall St.

a year ago

Sprinklr (NYSE:CXM) Shareholders Will Want The ROCE Trajectory To Continue

Viasat (VSAT) Launches Data Plans for Small-Scale Enterprises

Zacks

a year ago

Viasat (VSAT) Launches Data Plans for Small-Scale Enterprises

Guaranty Bancshares, Inc. Declares Quarterly Cash Dividend

Business Wire

a year ago

Guaranty Bancshares, Inc. Declares Quarterly Cash Dividend

Overseas Shipholding Group Installs Starlink Satellite Internet Service on Entire Fleet

Business Wire

a year ago

Overseas Shipholding Group Installs Starlink Satellite Internet Service on Entire Fleet

Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics

Business Wire

a year ago

Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics

Getting In Cheap On PlayAGS, Inc. (NYSE:AGS) Is Unlikely

Simply Wall St.

a year ago

Getting In Cheap On PlayAGS, Inc. (NYSE:AGS) Is Unlikely

Full Video Coverage – Healthcare Trends, Financing, Future Directions in 2024 Panel at 3rd Palm Beach CorpGov Forum

CorpGov.com

a year ago

Full Video Coverage – Healthcare Trends, Financing, Future Directions in 2024 Panel at 3rd Palm Beach CorpGov Forum

AGS Partners With Three Rivers Resort to Deliver An AGS-Exclusive Table Games Floor

GlobeNewswire

a year ago

AGS Partners With Three Rivers Resort to Deliver An AGS-Exclusive Table Games Floor

3 Off-the-Beaten-Path Stocks Poised for Substantial Growth

InvestorPlace

a year ago

3 Off-the-Beaten-Path Stocks Poised for Substantial Growth

Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Business Wire

a year ago

Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Returns On Capital Signal Difficult Times Ahead For China Yuchai International (NYSE:CYD)

Simply Wall St.

a year ago

Returns On Capital Signal Difficult Times Ahead For China Yuchai International (NYSE:CYD)

Share on Social Networks: